Please wait while the transcript is being prepared...
My name is Uma Lakshmipathy.
I'm with the stem cell
R&D at Life Technologies.
My research team is involved in the
development or reprogramming tools
and platforms for stem
Today, I would like to share
our studies on the use of gene
expression data for the
identification of novel markers
and for rapid characterization and
standardization of pluripotent stem
I'll start off with a brief
introduction on pluripotent stem
cells followed by current methods
used to characterize these cells.
I would then like to
share two recent studies.
The first study describes
development of a focus gene
expression panel for
and pluripotencies of
ESC and iPSC lines.
This method relies on monitoring
the expression of cell renewal
and lineage markers in
undifferentiated pluripotent cells
and in their corresponding
The second study is focused
on identification of CD44
as a negative mark
of pluripotent cells.
Pluripotent stem cells, or PSCs,
are cells that have the potential
to differentiate into nearly every
type of cell found in the body.
This potential makes them
valuable research tools
for many different applications,
including drug discovery, disease
modeling, and regenerative medicine.
Prior to 2006, the primary
source of pluripotent stem cells
was embryonic stem cells,
or ESCs, which are harvested
from the inner cell mass of a
blastocyst early stage embryo.
In 2006, Shinya
Yamanaka and colleagues
published a landmark paper
describing the derivation
of induced pluripotent stem
cells, or iPSCs, by reprogramming.
Reprogramming is a process
wherein an adult somatic cell,
such as a dermal fibroblast, can
be induced to turn into a cell that
is pluripotent and is essentially
indistinguishable from an ESC.